Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Earnings Per Share Diluted of $14.57 (loss) per share for the year ending 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +91.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Tonix Pharmaceuticals Holding Corp.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $0.07 (loss) per share | Q2 2021: $2.25 (loss) per share | Q3 2021: $1.60 (loss) per share | Q1 2022: $1.61 (loss) per share | Q2 2022: $7.64 (loss) per share | Q3 2022: $4.24 (loss) per share | Q1 2023: $3.21 (loss) per share | Q2 2023: $49.23 (loss) per share | Q3 2023: $38.63 (loss) per share | Q1 2024: $535.72 (loss) per share | Q2 2024: $1,920.85 (loss) per share | Q3 2024: $22.68 (loss) per share | Q1 2025: $2.84 (loss) per share | Q2 2025: $3.86 (loss) per share | Q3 2025: $3.59 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Tonix Pharmaceuticals Holding Corp.'s Earnings Per Share Diluted has declined by 79.9%.
- Historical annual values: Fiscal year 2025: $14.57 (loss) per share | Fiscal year 2024: $176.60 (loss) per share | Fiscal year 2023: $14,720.25 (loss) per share | Fiscal year 2022: $20.01 (loss) per share | Fiscal year 2021: $8.10 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: